Doubt the hedge funds that own about 40% of the outstanding shares are " babes in the woods " . If they are then I've made a serious miscalculation . I think they are all about 1) establish a ramp up in scripts to dialysis patients in the first year ...ramp up possible for all the reasons previously identified 2) file for patent extension as soon as FDA approved 3) sell to highest bidder ..probably Novartis ..once sales / scripts have ramped and the patent is extended to 2035 in the US and Europe 4 ) Try and get Stumble to see his stake asap so they can flip it for $60 a share when 1 and 2 are done ...OK scratch that :--)
Market Data 
Markets 
AI
